NASDAQ:DRMA Dermata Therapeutics (DRMA) Stock Price, News & Analysis $1.16 0.00 (0.00%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$1.15 -0.01 (-0.86%) As of 09/18/2026 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and TrendsOwnershipSEC Filings About Dermata Therapeutics Stock (NASDAQ:DRMA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Dermata Therapeutics alerts:Sign Up Key Stats Today's Range$1.14▼$1.1950-Day Range$1.08▼$1.7252-Week Range$0.95▼$5.87Volume5,561 shsAverage Volume69,926 shsMarket Capitalization$4.66 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Dermata Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for dermatological diseases and conditions. The company’s research is centered on topical therapies designed to address unmet needs in areas such as acne, psoriasis and other inflammatory or medical skin disorders. Dermata’s lead product candidate, DMT310, is a topical treatment platform being investigated for conditions including acne vulgaris and plaque psoriasis. The company has also developed additional topical product candidates, including DMT410, which has been studied for dermatological conditions involving excessive sweating. Its approach is intended to support localized treatment and potentially improve the delivery of active ingredients to the skin. Founded in 2014 and headquartered in San Diego, California, Dermata has conducted its development activities primarily in the United States. The company has advanced its candidates through clinical development and has worked with dermatology-focused research and commercial partners. Gerald Proeber has served as the company’s president and chief executive officer.AI Generated. May Contain Errors. Read More Dermata Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks11th Percentile Overall ScoreDRMA MarketRank™: Dermata Therapeutics scored higher than 11% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingDermata Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageDermata Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Dermata Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Dermata Therapeutics is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dermata Therapeutics is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDermata Therapeutics has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Dermata Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.32% of the float of Dermata Therapeutics has been sold short.Short Interest Ratio / Days to CoverDermata Therapeutics has a short interest ratio ("days to cover") of 1.18, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Dermata Therapeutics has recently decreased by 54.41%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDermata Therapeutics does not currently pay a dividend.Dividend GrowthDermata Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows1 people have added Dermata Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Dermata Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders21.90% of the stock of Dermata Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions8.67% of the stock of Dermata Therapeutics is held by institutions.Read more about Dermata Therapeutics' insider trading history. Receive DRMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dermata Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DRMA Stock News HeadlinesDermata Therapeutics announces $3.4M private placementAugust 17, 2026 | msn.comDRMA Share News TodayAugust 7, 2026 | uk.investing.comYou’ve never seen anything like this beforeFor centuries, families like the Rothschilds, Morgans, and Rockefellers have quietly used one overlooked type of finance to build lasting wealth. Legendary investor Joel Greenblatt calls it 'the closest thing to a perpetual motion machine you will ever see.' One investor famously turned 50000 dollars into 900 million using this approach. Porter Stansberry breaks down its origins and mechanics in a new free documentary.September 20 at 1:00 AM | Porter & Company (Ad)Dermata Therapeutics Inc Share Price (DRMA.US)August 7, 2026 | lse.co.ukDermata Therapeutics Insider Trading Activity | NASDAQ:DRMA | BenzingaApril 12, 2026 | benzinga.comDermata Therapeutics (DRMA) price target decreased by 60.00% to 4.08April 9, 2026 | msn.comDermata Therapeutics: Dermata Announces Appointment of Kyra Peckaitis as Vice President, MarketingMarch 10, 2026 | finanznachrichten.deDermata Therapeutics: Dermata Opens a New Chapter with the Release of Tome SkincareMarch 5, 2026 | finanznachrichten.deSee More Headlines DRMA Stock Analysis - Frequently Asked Questions How have DRMA shares performed this year? Dermata Therapeutics' stock was trading at $2.32 at the start of the year. Since then, DRMA shares have decreased by 50.0% and is now trading at $1.16. How were Dermata Therapeutics' earnings last quarter? Dermata Therapeutics, Inc. (NASDAQ:DRMA) announced its earnings results on Tuesday, August, 11th. The company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.55) by $0.19. When did Dermata Therapeutics' stock split? Dermata Therapeutics shares reverse split before market open on Thursday, May 16th 2024.The 1-15 reverse split was announced on Thursday, May 16th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Dermata Therapeutics IPO? Dermata Therapeutics (DRMA) raised $21 million in an initial public offering (IPO) on Friday, August 13th 2021. The company issued 2,571,428 shares at a price of $7.00-$9.00 per share. How do I buy shares of Dermata Therapeutics? Shares of DRMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Dermata Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dermata Therapeutics investors own include BIOLASE (BIOL), CNS Pharmaceuticals (CNSP), Esports Entertainment Group (GMBL), Jiuzi (JZXN), Kiora Pharmaceuticals (KPRX), ENDRA Life Sciences (NDRA) and Sonnet BioTherapeutics (SONN). Company Calendar Last Earnings8/11/2026Today9/20/2026Next Earnings (Estimated)11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (10m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 DRMA's financial health is in the Red zone, according to TradeSmith. DRMA has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorConsumer Staples Industry Personal Care Products Sub-IndustryPersonal Care Products Current SymbolNASDAQ:DRMA CIK1853816 Webwww.dermatarx.com Phone858-800-2543FaxN/AEmployees9Year Founded2014Profitability EPS (Trailing Twelve Months)($4.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.56 million Net MarginsN/A Pretax MarginN/A Return on Equity-166.66% Return on Assets-130.13% Debt Debt-to-Equity RatioN/A Current Ratio2.81 Quick Ratio2.73 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.19 per share Price / Book0.53Miscellaneous Outstanding Shares4,020,000Free Float3,141,000Market Cap$4.66 million OptionableNot Optionable Beta0.69 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:DRMA) was last updated on 9/20/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | Sponsored“Elon’s nightmare” could fund your retirementMarc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredYou’ve never seen anything like this beforeFor centuries, families like the Rothschilds, Morgans, and Rockefellers have quietly used one overlooked type ...Porter & Company | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredNVDA CEO says it’s a "once-in-a-generation opportunity"NVIDIA CEO Jensen Huang calls a little-known AI niche a once-in-a-generation opportunity, and it has nothing t...Monument Traders Alliance | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dermata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dermata Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
